Not Yet RecruitingNot Applicable

Sclerotherapy and Candida Antigen in Treatment of Common Warts

Egypt75 participantsStarted 2024-12-20

Plain-language summary

This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age group: \>18years. * Confirmed diagnosis by clinical and dermoscopic examination of common wart will be made. Exclusion Criteria: * Patients who receive any treatment for wart in the last month before the study. * Patients with history of renal or liver disease. * Patients with any evidence of bleeding diathesis, vaso-occulusive or thrombo-embolic disorders. * Pregnant and lactating females. * Patients who receive immunosuppressive therapy. * Patients' refusal. * Patients with history or evidenced hypersensitivity to any component used in this study.

What they're measuring

size of warts

Timeframe: session every 2 weeks until complete clearance of warts or for a maximum of 6 treatment sessions and one month after last session

Trial details

NCT IDNCT06749665

SponsorSohag University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-01

Contact for this trial

Heba S Osman

01013846228 heba_shawky_post@med.sohag.edu.eg

View on ClinicalTrials.gov More Common Wart trials